KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $6.3 million.

  • TherapeuticsMD's Goodwill & Intangibles fell 197.34% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 197.34%. This contributed to the annual value of $6.4 million for FY2024, which is 1995.23% down from last year.
  • Per TherapeuticsMD's latest filing, its Goodwill & Intangibles stood at $6.3 million for Q3 2025, which was down 197.34% from $6.3 million recorded in Q2 2025.
  • TherapeuticsMD's 5-year Goodwill & Intangibles high stood at $48.4 million for Q3 2022, and its period low was $6.3 million during Q3 2025.
  • Moreover, its 5-year median value for Goodwill & Intangibles was $8.0 million (2023), whereas its average is $19.5 million.
  • As far as peak fluctuations go, TherapeuticsMD's Goodwill & Intangibles soared by 65061.39% in 2021, and later tumbled by 8625.89% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's Goodwill & Intangibles stood at $8.2 million in 2021, then grew by 4.34% to $8.5 million in 2022, then fell by 6.7% to $8.0 million in 2023, then dropped by 19.95% to $6.4 million in 2024, then dropped by 1.88% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, $6.3 million for Q2 2025, and $6.3 million during Q1 2025.